Involuntary Prenatal Oxycodone Exposure Increases Addiction Risk in Rat Offspring

Maternal Agency and the Intergenerational Path of Opioid Exposure

The clinical management of opioid use during pregnancy remains a complex challenge, as intrauterine exposure is frequently associated with long-term neurobehavioral impairments and increased psychiatric vulnerability in children [1, 2]. While the Centers for Disease Control and Prevention guidelines emphasize stabilizing maternal health to mitigate neonatal risks [3], the specific factors driving diverse developmental trajectories remain poorly understood. Comparative data suggest that treatment choice significantly impacts neonatal outcomes, with buprenorphine associated with a lower risk of preterm birth (relative risk 0.40, 95% CI 0.18 to 0.91) and increased birth weight (weighted mean difference 277 g, 95% CI 104 to 450) compared to methadone [4]. Furthermore, the transmission of stress-related phenotypes (observable behavioral traits resulting from the interaction of genetics and environment) is heavily influenced by maternal resilience and family functioning [5, 6, 7]. Because the degree of control over a stressor often dictates physiological adaptation [8], a new study investigates how the mode of maternal opioid administration, specifically voluntary versus involuntary intake, shapes the future addiction risk of the developing fetus.

Modeling Contingent Versus Non-Contingent Prenatal Exposure

To investigate how maternal agency influences fetal development, researchers utilized a translational rat model involving female Sprague-Dawley rats. The study cohort consisted of 31 to 33 dams, which were assigned to one of three distinct experimental groups (n = 10 to 11 per group) to isolate the effects of drug contingency, defined as the degree of control an individual has over their drug intake. The first group, designated as Oxycodone-Lead, was allowed voluntary intravenous self-administration of the opioid. The second group, Oxycodone-Yoked, received non-contingent or involuntary oxycodone delivery that was precisely matched to the dosage and timing of the Lead group. The third group, Saline-Yoked, served as a control, receiving involuntary infusions of saline to account for the physiological stress of the intravenous procedure.

The administration protocol was designed to mimic chronic use patterns seen in clinical populations. The dams underwent 6-hour sessions for five days per week over a three-week period prior to conception, ensuring a baseline of opioid exposure before pregnancy began. Once pregnant, the dams continued to receive oxycodone or saline daily throughout the entire gestation period. This rigorous schedule allowed the researchers to maintain equivalent overall drug exposure between the voluntary and involuntary groups, thereby isolating the psychological and physiological impact of maternal control from the total pharmacological load.

To ensure that the observed behavioral outcomes in the offspring were strictly the result of prenatal exposure rather than differences in postnatal maternal care, the researchers employed a cross-fostering procedure. At birth, all offspring were removed from their biological mothers and placed with drug-naïve dams. This methodological step was critical for isolating the neurodevelopmental trajectories established in utero. By removing the variable of postpartum maternal behavior, the study could more accurately determine how the mode of maternal oxycodone intake during pregnancy independently programmed the adult offspring's vulnerability to substance use.

Assessing Adult Offspring Vulnerability to Substance Use

To evaluate the long-term behavioral consequences of prenatal opioid exposure, the researchers conducted a series of behavioral assays on adult male and female offspring. These tests were designed to measure both the acquisition of drug-taking behavior and the intensity of the drive to obtain substances. The offspring were evaluated for intravenous self-administration of oxycodone at a dose of 0.1 mg/kg/infusion to assess opioid-specific vulnerability. Additionally, the researchers tested the offspring for intravenous self-administration of cocaine at a dose of 0.5 mg/kg/infusion, a protocol used to determine if the neurodevelopmental changes induced by prenatal oxycodone exposure extended to other classes of addictive substances.

The self-administration protocol utilized specific reinforcement schedules to quantify different aspects of addiction-like behavior. Testing began with 7 sessions of fixed ratio 1 (FR1), a schedule where every single lever press results in a drug infusion, followed by 5 sessions of fixed ratio 5 (FR5), which requires five responses for each infusion. These fixed ratio schedules allow researchers to observe how readily an individual establishes a stable pattern of drug intake. To measure motivated responding, which represents the maximum effort an animal is willing to exert to obtain a single dose of the drug, the researchers employed progressive ratio schedules over 3 sessions. In these sessions, the response requirement increases exponentially for each subsequent infusion, providing a clear metric of the animal's motivation or break point for the substance.

The final phase of the behavioral assessment focused on the persistence of drug-seeking when the substance was no longer available. Drug-seeking under extinction conditions was evaluated in 1 session, during which the researchers recorded the number of responses made even though no drug was delivered. This measure is particularly relevant to clinical practice, as it models the propensity for relapse and the difficulty of extinguishing drug-related behaviors. Ultimately, the study found that offspring of Oxycodone-Yoked dams exhibited enhanced motivated responding and drug-seeking behaviors compared to the other groups, suggesting that the psychological context of maternal drug use is a critical determinant of the offspring's future substance use risk.

Involuntary Exposure Drives Enhanced Drug-Seeking Behavior

The study demonstrated that the psychological context of maternal drug use, specifically the lack of agency over administration, was a more potent predictor of offspring vulnerability than the pharmacological exposure alone. Although the researchers ensured that overall drug exposure was equivalent between the Oxycodone-Lead and Oxycodone-Yoked maternal groups, the behavioral outcomes in their progeny differed significantly. The researchers found that offspring of Oxycodone-Yoked dams exhibited enhanced motivated responding and drug-seeking behaviors compared to both the Oxycodone-Lead and Saline-Yoked control groups. This suggests that the maternal stress or physiological dysregulation associated with non-contingent drug delivery creates a distinct neurodevelopmental environment that increases the risk of substance use disorders in the next generation.

Sex-specific vulnerabilities were particularly evident in the response to opioids. The researchers noted that female Oxycodone-Yoked offspring showed increased intake and motivated responding specifically for oxycodone, suggesting a heightened sensitivity to the reinforcing properties of opioids in females following involuntary prenatal exposure. Furthermore, the impact of this exposure was not limited to opioids. Oxycodone-Yoked offspring of both sexes displayed augmented cocaine seeking, indicating a cross-sensitization effect where prenatal opioid exposure increases the drive for other classes of stimulants. This heightened vulnerability was further confirmed during withdrawal testing, as Oxycodone-Yoked offspring of both sexes displayed augmented drug-seeking under extinction conditions. For clinicians, this translates to a modeled persistence of drug-craving and a high risk of relapse even when the substance is no longer available.

Clinical Implications of Maternal Behavioral Context

The researchers utilized Pearson's correlations, a statistical measure of the strength of a linear relationship between two variables, to examine the link between the amount of oxycodone the mothers received and the subsequent behavior of their adult offspring. These correlations between maternal intake and offspring behavior were sex-specific and drug-specific, indicating that the relationship between prenatal exposure levels and later addiction risk is not uniform across different substances or between male and female progeny. Notably, these correlations between maternal intake and offspring behavior were only observed in the Oxycodone-Yoked group, where mothers had no control over drug delivery. In the group where mothers self-administered the drug, the volume of intake did not correlate with offspring outcomes in the same way, suggesting that the involuntary nature of the exposure fundamentally alters the dose-response relationship.

These findings suggest that maternal control over drug intake, rather than opioid exposure per se, plays a critical role in shaping neurodevelopmental trajectories that underlie substance use vulnerability. For the practicing physician, this distinction emphasizes that the pharmacological dose of an opioid during pregnancy may be less predictive of long-term pediatric outcomes than the behavioral and psychological context of the mother's use. While maternal toxicology screens provide a snapshot of exposure, they do not account for the physiological stress or lack of agency associated with non-contingent drug use. Consequently, assessing developmental risk in children requires a detailed maternal history that includes the patterns and context of opioid use, as the lack of maternal autonomy over drug administration appears to be a primary driver of increased motivated drug-seeking and relapse risk in the next generation.

References

1. Hjorth S, Bromley R, Ystrøm E, Lupattelli A, Spigset O, Nordeng H. Use and validity of child neurodevelopment outcome measures in studies on prenatal exposure to psychotropic and analgesic medications – A systematic review. PLoS ONE. 2019. doi:10.1371/journal.pone.0219778

2. Baldacchino A, Arbuckle K, Petrie D, McCowan C. Neurobehavioral consequences of chronic intrauterine opioid exposure in infants and preschool children: a systematic review and meta-analysis. BMC Psychiatry. 2014. doi:10.1186/1471-244x-14-104

3. Dowell D, Ragan K, Jones CM, Baldwin G, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain—United States, 2022. MMWR Recommendations and Reports. 2022. doi:10.15585/mmwr.rr7103a1

4. Zedler B, Mann AL, Kim M, et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐analysis of safety in the mother, fetus and child. Addiction. 2016. doi:10.1111/add.13462

5. Hajure M, Alemu SS, Abdu Z, et al. Resilience and mental health among perinatal women: a systematic review. Frontiers in Psychiatry. 2024. doi:10.3389/fpsyt.2024.1373083

6. Dashorst P, Mooren T, Kleber RJ, Jong PJD, Huntjens RJC. Intergenerational consequences of the Holocaust on offspring mental health: a systematic review of associated factors and mechanisms. European journal of psychotraumatology. 2019. doi:10.1080/20008198.2019.1654065

7. Messina N, Calhoun S, Conner E, Miller M. Improving the outcomes of children affected by parental substance abuse: a review of randomized controlled trials. Substance Abuse and Rehabilitation. 2015. doi:10.2147/sar.s46439

8. Vasconcelos M, Stein DJ, Almeida RMMD. Social defeat protocol and relevant biomarkers, implications for stress response physiology, drug abuse, mood disorders and individual stress vulnerability: a systematic review of the last decade. Trends in Psychiatry and Psychotherapy. 2015. doi:10.1590/2237-6089-2014-0034